Table of Contents

• Overview of the Valganciclovir trials
• Cancer studies
• CMV and transplant studies
• Heart surgery study
• Trial phases and study designs
• Main outcomes being measured
• Who can participate

Overview of the Valganciclovir trials

These clinical trials are testing Valganciclovir in several very different patient groups, not as a general medicine review but as a study treatment in specific research settings.^{[1][2][3][4][5][6]}

The trial data show research in EBV-positive relapsed/refractory lymphomas, CMV prevention after kidney transplant, CMV management after major heart surgery, CMV prevention in renal recipients at high risk after transplant, CMV treatment in kidney transplant recipients, and newly diagnosed glioblastoma.^{[1][2][3][4][5][6]}

Cancer studies

One Phase 2 trial, called NAVAL-1, studied Valganciclovir together with nanatinostat in patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas.^[1]

The main goal was to evaluate anti-tumor activity, which means whether the treatment helped shrink or control the cancer.^[1]

The primary outcome was objective response rate (ORR), measured by an Independent Review Committee using the 2007 International Working Group criteria.^[1]

Another Phase 2 trial studied Valganciclovir in people with newly diagnosed glioblastoma, with less than 1 cm3 of contrast-enhancing tumor left after surgery.^[6]

This study compared standard therapy plus Valganciclovir against standard therapy without it, using a placebo tablet for comparison.^[6]

The main endpoint was overall survival, measured from surgery until death from any cause, with the final analysis planned when the last patient reached 30 months of follow-up.^[6]

CMV and transplant studies

Several Phase 3 trials focused on CMV, which stands for cytomegalovirus.^[2][3][4][5]

In the CYTOPREV study, kidney transplant patients were studied to compare an immuno-guided prevention strategy with a universal prophylactic strategy, and the main outcome was the proportion of patients with CMV infection within 6 months after transplantation.^[2]

In another Phase 3 study, renal recipients at high risk of post-transplant CMV were studied, and the main endpoint was whether CMV infection or disease occurred within 6 months after transplant.^[4]

A third Phase 3 study tested letermovir plus Valganciclovir against Valganciclovir alone in kidney transplant recipients with CMV infection.^[5]

Its main outcome was virological response at Week 3, meaning a major drop in CMV DNA in the blood or no detectable CMV DNA below the study cutoff.^[5]

Heart surgery study

The GAN-CAR trial was a Phase 3 multicenter, double-blind, randomized clinical trial in high-risk immunocompetent adults after major heart surgery.^[3]

It studied targeted pre-emptive antiviral therapy for patients who had stayed at least 3 days in the cardiac surgery ICU and had CMV viral load.^[3]

The primary outcome was the number of days with a good outcome during 30 days of follow-up, where a good outcome meant the patient was alive, out of the ICU, not needing systemic antimicrobials, not on mechanical ventilation, and without serious adverse events.^[3]

Trial phases and study designs

The trial set includes both Phase 2 and Phase 3 studies, showing that Valganciclovir is being tested in both earlier and later stages of clinical research.^{[1][2][3][4][5][6]}

Some trials are interventional, which means the researchers assign a treatment strategy and then measure results.^{[1][2][3][4][5][6]}

One study used a combination treatment with nanatinostat, while another used Valganciclovir with letermovir, and some studies compared Valganciclovir with placebo or with different prevention strategies.^[1][5][6]

Main outcomes being measured

The studies measure different endpoints depending on the disease being treated.^{[1][2][3][4][5][6]}

• Objective response rate in lymphoma, which shows how many patients had a measurable cancer response.^[1]

• CMV infection within 6 months after kidney transplant, used to test prevention strategies.^[2][4]

• Good outcome days after heart surgery, which captures recovery and serious illness in the first 30 days.^[3]

• Virological response at Week 3 in kidney transplant recipients with CMV infection, based on CMV DNA levels in blood.^[5]

• Overall survival in glioblastoma, measured from surgery until death from any cause.^[6]

Who can participate

Each study has a different target population, so eligibility depends on the condition being studied.^{[1][2][3][4][5][6]}

People in these trials include patients with EBV-positive relapsed or refractory lymphomas, kidney transplant recipients, renal recipients at high risk of CMV, immunocompetent adults after major heart surgery, and newly diagnosed glioblastoma patients with very small remaining tumor after surgery.^{[1][2][3][4][5][6]}

The enrollment sizes range from 30 to 502 participants, showing that some studies are small and focused, while others include larger groups.^{[1][2][3][4][5][6]}